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ABSTRACT 
 
The Apoptotic and Inhibitory Effects of Phylloquinone in the U937 Cell Line 
 
by  
 
Tesha Blair 
 
Phylloquinone is a natural analog of vitamin K that has been shown to both inhibit 
cancer cell growth and induce apoptosis in several cancer cell lines. This study 
examined these effects in a non-Hodgkin lymphoma cell line, known as U937. Cell 
growth inhibition and apoptosis were assessed through the quantification of cell 
density and area, following treatment with several concentrations of phylloquinone. 
In addition, apoptosis was detected and quantified using immunofluorescent 
markers of apoptosis (i.e. annexin V, APO-BrdU). Treatment with phylloquinone 
resulted in reduced overall cell density, increased overall cell area, and an increased 
frequency of apoptosis in U937 cells. Increasing both phylloquinone concentration 
and treatment time enhanced these effects. These results are significant because 
they document the anti-cancer effects of this analog of vitamin K, as well as provide 
insight into the morphological changes that occur during apoptosis in U937 cells.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
The National Institute of Health estimates the allocation of $9.3 billion 
dollars to fund cancer-related research for the year of 2017 (National Institute of 
Health 2016). This comes as no surprise, considering the millions of cancer fatalities 
worldwide every year. Risk factors like nutritional deficiencies, environmental 
toxins, transmission of disease, and an ever-growing and aging population directly 
contribute to the rising number of new cancer cases (Peterson et al. 2012; Howell et 
al. 2014; American Cancer Society 2015). The World Health Organization predicts 
that by 2035, the worldwide rates of cancer morbidity and mortality will reach 24 
million and 14.6 million, respectively (National Cancer Institute 2015). In order to 
combat this epidemic, more effective and accessible treatments need to be 
developed. Many researchers are currently interested in the relationship between 
cell proliferation and cell death – specifically, the dysregulation of genetically 
directed cell death pathways, like apoptosis, in the proliferation of aberrant cells, 
and how this relationship can be used to design more promising cancer treatment 
therapies (Lowe and Lin 2000).  
 
 
Apoptosis 
 
The earliest documentation of cell death dates back to 1842, when a German 
scientist named Carl Vogt published a study on the degeneration of cells during 
metamorphosis of the common midwife toad (Alytes obstetricans) (Clarke and 
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Clarke 2012). A little over forty years later, another German scientist named Walter 
Flemming characterized the morphological changes of non-necrotic cell death in his 
publication on ovarian follicular cell atresia, which is a normal process of 
menstruation (Lockshin and Zakeri 2001). It was not until 1972 that the term 
“apoptosis” was first proposed by pathologists John Foxton Ross Kerr, Andrew H. 
Wyllie, and Alastair Robert Currie, to describe a type of cell death morphologically 
separate from necrosis, as well as one that is fundamental to the homeostatic 
balance between cell division and cell death in normal animal cell populations (Kerr 
et al. 1972; Bold et al. 1997; Jiang 2011). Since the recognition that apoptosis is a 
genetically regulated event that occurs both during normal development and aging, 
and in response to various internal and external stimuli, many scientists have been 
interested in the factors affecting this type of cell death, as well as the biochemical 
and molecular pathways coordinating their effect (Williams and Smith 1993; Elmore 
2007). 
Kerr, Wyllie, and Currie derived the term “apoptosis” from the Greek word 
“αποπτωσισ”, which translates to the “dropping off” or “falling off” of flower petals 
or tree leaves, to describe the structural changes they observed in a variety of 
tissues with electron microscopy, including neonatal rat adrenal cortexes and 
human neoplasms (Kerr et al. 1972). This derivation was likely selected because it 
implies that the death or loss of a specific part of an organism is fundamental to the 
continuation of its life cycle. Prior to this time, the morphology of cell death 
described in most scientific texts was characteristic of coagulative or classical 
necrosis, and therefore apoptosis was seen as a distinct subtype of necrosis, known 
 13 
as “shrinkage necrosis”, with markedly different morphological changes (Kerr 1971; 
Kerr 2002). The process of apoptosis, as first described by Kerr, Wyllie, and Currie 
in 1972, generally affects individual cells scattered throughout cell populations, and 
occurs in two discrete stages. The first stage consists of the formation of apoptotic 
bodies, which are preserved cellular fragments containing organelles, condensed 
cytoplasm, and/or condensed nuclear chromatin, which are chemically and 
structurally intact. The second stage of apoptosis consists of the phagocytosis and 
subsequent degradation of apoptotic bodies by nearby cells (Kerr et al. 1972; Kerr 
et al. 1994). 
 
 
Morphology 
The formation of apoptotic bodies occurs through a series of coordinated 
events. The apoptotic cell undergoes simultaneous nuclear shrinkage or pyknosis, 
membrane blebbing or the appearance of protrusions along the cell’s surface, and 
cytoplasmic condensation (Kerr et al. 1972). This is followed by nuclear 
fragmentation or karyorrhexis, and finally, the separation of protuberances along 
the cell’s surface to form membrane-bound apoptotic bodies (Kerr et al. 1972; 
Majno and Joris 1995).  The term “budding” has also been used to refer to the 
formation of apoptotic cell bodies (Kerr et al. 1994; Majno and Joris 1995).  
Apoptotic bodies can contain any cellular components that were near or in the 
cytoplasmic protrusion before budding occurred, including cytoplasmic elements, 
condensed organelles, and condensed nuclear chromatin. Although size and 
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composition is highly variable between bodies, the structural and chemical integrity 
of their contents is preserved (Kerr et al. 1972; Kerr et al. 1994).  
Following the release of chemoattractants and surface signals, apoptotic 
bodies are rapidly phagocytized by a variety of adjacent cell types, including 
macrophages, neoplastic cells, epithelial cells, or fibroblasts, and undergo lysosomal 
degradation (Kerr et al. 1972; Majno and Joris 1995; Elmore 2007; Elliot and 
Ravichandran 2010). A renowned feature of apoptosis is that, unlike necrosis, no 
inflammation results from the displacement of cellular bodies (Kerr et al. 1994; 
Majno and Joris 1995).  There are several reasons why apoptosis does not provoke 
an inflammatory response: (1) apoptotic bodies are membrane-bound, so cellular 
contents are not spilled into interstitial tissues surrounding the cell, (2) bodies are 
quickly engulfed by nearby cells, inhibiting secondary necrosis, and (3) anti-
inflammatory cytokines are not produced by phagocytic cells (Martin and Green 
1995; Elmore 2007; Silva 2010). Due to this lack of inflammation, apoptosis 
represents a promising way to ensure specific cell death without damage to 
surrounding healthy tissues.  
 
 
Programmed Cell Death and Cell Suicide – Incidence of Apoptosis 
Programmed cell death (PCD) and cell suicide are both terms used to 
describe apoptosis, although they have alternate connotations. PCD denotes cell 
death that is genetically predetermined, while cell suicide implies an inducible or 
spontaneous form of cell death. The pervasiveness of these expressions has led to 
some ambiguity in regards to the circumstances surrounding apoptosis (Majno and 
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Joris 1995). In truth, apoptosis can be predetermined or inducible depending on the 
life stage of the organism and its environment. This type of cell death has two major 
roles – one is to ensure the existence of healthy cells, the other is to diminish the 
existence of unhealthy ones (Kerr et al. 1994). In this way, PCD can generally be 
applied to the role of apoptosis in healthy cell populations, while cell suicide can be 
used to depict the role of apoptosis in unhealthy ones. 
Apoptosis ensures the proliferation of healthy cells through the regulated 
deletion of cells that are overabundant, or cells that have lost their function or 
become superfluous over time (Kerr et al. 1972; Martin and Green 1995). During 
ontogenesis, and particularly throughout embryogenesis, the controlled deletion of 
overabundant cells is necessary for shaping an organism’s developing tissues and 
organs (Martin and Green 1995; Abud 2004). A renowned example of apoptosis 
during embryogenesis occurs in primates, where one of its many responsibilities is 
the elimination of the interdigital webbing of the hand or foot to form fingers and 
toes (Dorn 2013). Apoptosis is also critical to the excision of cells that are no longer 
needed or have lost their function during events like metamorphosis and aging 
(Martin and Green 1995).  During amphibian metamorphosis, for example, this type 
of cell death is responsible for the removal of the tadpole’s tail as it matures into an 
adult frog (Kerr et al. 1974). These events provide examples of apoptosis that are 
genetically programmed or predetermined, and are essential to the growth or 
maintenance of healthy cell populations.  
 Apoptosis diminishes the existence of unhealthy or abnormal cells in 
response to a number of factors, including mutation and disease (Martin and Green 
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1995; Elmore 2007). It goes without saying that the accumulation of aberrant cells 
compromises the body’s ability to defend itself. Therefore, in individuals with 
normal physiology, the induction of apoptosis is one of first lines of defense in or 
against cells that are structurally and functionally damaged (Kerr et al. 1994). 
Without this inducible form of cell death, cell populations would accumulate more 
mutations and be more susceptible to a variety of diseases. For instance, there is a 
strong correlation between modified apoptotic pathways resulting in less cell death 
and an increased incidence of cancer (Kerr et al. 1994; Bold et al. 1997). Other 
examples of the relationship between reduced apoptosis and enhanced morbidity 
include increased susceptibility to viral infection, like Epstein-Barr and adenovirus, 
as well as to autoimmune disease, like lupus and rheumatoid arthritis (Solary et al. 
1996). Typically, the ability to engage in cell suicide is beneficial to the specific cell 
population, and therefore, many pathologic states arise from an inability to engage 
in this form of cell death. There are instances, however, when modifications causing 
the upregulation of this cell death pathway can accelerate the progression of a 
disorder or disease (Elmore 2007). This is exemplified by viruses that can induce 
apoptosis to aid in their own propagation, by either causing an infected cell to die 
and release its viral constituents (e.g. Avian Reovirus) or causing the death of an 
immune cell, so that it is unable to phagocytize the virus (e.g. HIV and influenza A 
and B viruses) (Hinshaw et al. 1994; Elmore 2007; Rodríguez-Grille et al. 2014). 
These examples provide evidence of the role of this inducible form of cell death in 
diminishing the existence of unhealthy cells, as well as the some of the 
consequences of modulations to these pathways. 
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Biochemical Mechanisms 
 The mechanisms of apoptosis can be divided into two major pathways: the 
extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway 
(Elmore 2007). Both pathways are mediated by caspases, a group of cysteine 
proteases, which remain in their zymogenic form until they receive an apoptotic 
stimulus (Johnstone et al. 2002). Once active, caspases engage in a caspase cascade 
where upstream or initiator caspases (e.g. caspases 2, 8, 9, 10) cleave downstream 
or effector caspases (e.g. caspases 3, 6, 7), which, in turn, cleave various cellular 
proteins that regulate apoptotic cell death (Chang and Yang 2000; Turk and Stoka 
2007). The extrinsic pathway of apoptosis is initiated when an extrinsic ligand binds 
to a membrane-bound member of the tumor necrosis factor (TNF) receptor 
superfamily (e.g. TRAIL receptor 1, Fas receptor), which is commonly referred to as 
a “death receptor” (Johnstone et al. 2002; Wang and El-Deiry 2003). Binding of these 
receptors results in the activation of initiator caspases 8 and 10, which activate 
effector caspases 3 and 7 (Johnstone et al. 2002). These caspases then activate a 
network of proteins and orchestrate numerous processes that lead to apoptotic cell 
death (Chang and Yang 2000; Elmore 2007).  
The intrinsic pathway of apoptosis is initiated when the cell is exposed to 
DNA damage, free radicals, radiation, viral infections, and other types of cell stress 
(Wang and El-Deiry 2003). These stimuli activate pro-apoptotic members of the Bcl-
2 superfamily (e.g. PUMA, Bax, Bak), which modify the integrity of the inner 
mitochondrial membrane and result in the release of several pro-apoptotic proteins 
(e.g. cytochrome c, Smac, Omi) into the cytosol (Johnstone et al. 2002; Turk and 
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Stoka 2007). Cytochrome c activates apaf1, which is needed for the formation of an 
apoptosome, a quaternary protein structure containing cytochrome c and apaf1, and 
the activation of initiator caspase 9 (Johnstone et al. 2002; Turk and Stoka 2007). 
The activation of caspase 9 triggers a caspase cascade and activates effector 
caspases 3, 6, and 7, whilst Smac and Omi bind to and antagonize several anti-
apoptotic proteins (Johnstone et al. 2002). Again, this cascade ultimately leads to 
activation and induction of a variety of proteins and processes that lead to apoptotic 
cell death (Chang and Yang 2000; Elmore 2007). There is evidence of crosstalk 
between the pathways: caspase 8 can activate another Bcl-2 family member, Bid, 
which can induce the release of cytochrome c in the mitochondria through 
interaction with Bax and Bak (Johnstone et al. 2002; Wang and El-Deiry 2003).  
A third apoptotic pathway does exist, but it is limited to natural killer cells 
and cytotoxic T cells. These cells secrete a serine protease called granzyme B, which 
is similar to caspases because they both cleave other proteins directly following an 
aspartic acid residue (Turk and Stoka 2007). When natural killer cells or cytotoxic T 
cells encounter a target cell, they can secrete granzyme B, along with perforin, and 
engage in the extrinsic pathway through cleavage of caspase 3 or in the intrinsic 
pathway through cleavage of Bid (Turk and Stoka 2007). Another serine protease, 
granzyme A, is secreted by cytotoxic T cells and can induce apoptosis through a 
caspase independent pathway involving tumor suppressor gene, NM23-H1 (Elmore 
2007). Granzyme A cleaves NM23-H1 antagonist SET, which activates NM23-H1 and 
results in apoptotic DNA degradation (Elmore 2007).  
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Apoptosis and Cancer 
 
Apoptosis is fundamental to the homeostasis of healthy cell populations – 
that is, the balance between cell growth and division, as well as cell death. Any 
disruption to this balance will therefore result in numerous pathologic states, 
including cancer (Kerr et al. 1972; Alberts et al. 2002). Cancer is the result of defects 
or modifications to genes controlling cell proliferation and differentiation, as well as 
those controlling cell death (Martin and Green 1995). With regards to cell death, 
specifically apoptosis, there are two major categories of genes: repressors or anti-
apoptotic genes and inducers or pro-apoptotic genes. As their names suggest, 
repressors inhibit or postpone apoptosis, while inducers provoke it or increase the 
likelihood that it will occur (Martin and Green 1995). Mutations or modifications to 
the expression levels of repressors and/or inducers in both apoptotic pathways, as 
well as their upstream and downstream components, are common to many cancer 
and tumor types, although these changes more often occur in members of the 
intrinsic or mitochondrial pathway (Martin and Green 1995; Johnstone et al. 2002).  
The p53 tumor suppressor gene is a checkpoint protein that is essential to 
the regulation of both the cell cycle and cell death (Kerr et al. 1994; Bold et al. 1997; 
Lowe and Lin 2000). p53 allows cells to respond to DNA damage by arresting the 
cell cycle and attempting DNA repair, when its levels are low or moderate, and 
inducing apoptosis when its levels are high (Bold et al. 1997). The wild-type p53 
allele is an intrinsic inducer of apoptosis and is responsible for the transcriptional 
activation of Bcl-2 family inducers (e.g. Bax, Bak, PUMA) and repression of Bcl-2 
family suppressors (e.g. Bcl-2, Bcl-X) (Johnstone et al. 2002). The loss of function 
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that occurs in mutant p53 alleles has been found to both inactivate apoptosis and 
accelerate tumor formation, and has been observed in the vast majority of human 
cancer types, including lung, colon, breast, prostate, and pancreas, (Bold et al. 1997; 
Lowe and Lin 2000; Johnstone et al. 2002). For this reason, functional mutations of 
p53 are associated with advanced stage cancer and high mortality (Lowe and Lin 
2000). In addition to changes in p53 itself, mutations or modified expression of its 
upstream regulators (e.g. ATM, Mdm 2) or downstream effectors (e.g. Bax, Bak, 
Apaf1) have been found in many tumor types including leukemia and melanoma, as 
well as colon, gastric, and breast cancers (Lowe and Lin 2000; Johnstone et al. 
2002). 
 Functional mutations or altered expression of Bcl-2 family members are also 
associated with cancer cell proliferation through a failure to induce apoptosis (Lowe 
and Lin 2000; Johnstone et al. 2002). In mammalian cells, fifteen Bcl-2 family 
members have been identified and consist of both repressors and inducers of 
apoptotic cell death (Lowe and Lin 2000). Bcl-2, itself, was originally characterized 
as a proto-oncogene because of its location on a breakpoint in human B-cell 
lymphomas, following chromosomal translocation (Kerr et al. 1994; Lowe and Lin 
2000). Bcl-2 was later determined to inhibit apoptosis, rather than promote 
proliferation, in interleukin-3-depedent myeloid and lymphoid cell lines, following 
interleukin-3 deprivation (Ascaso et al. 1994; Kerr et al. 1994; Lowe and Lin 2000).  
Bcl-2 is an intrinsic repressor of apoptosis, and its overexpression has been 
significantly associated with both cancer development and metastasis, and has been 
estimated to occur in approximately half of all cancers (Bold et al. 1997; Johnstone 
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et al. 2002; Yip and Reed 2008). The inactivation or reduced expression of Bcl-2 
family inducers of apoptosis, like Bax and Bak, result in an inability to suppress 
tumor growth by the induction of apoptosis, and have been identified in different 
tumor types, including colon, stomach, breast, gastric and hematopoietic cancers 
(Ouyang et al. 1998; Lowe and Lin 2000; Johnstone et al. 2002; Yip and Reed 2008; 
Kholoussi et al. 2014). Like p53, changes to the expression or function of Bcl-2 
upstream components are associated with the dysregulation of apoptosis and result 
in tumorigenesis (Johnstone et al. 2002).  
Disturbances to members of the extrinsic or death receptor apoptotic 
pathway are less common, although they have been found in tumor cells and result 
in an inability to undergo apoptosis following the binding of death receptors 
(Johnstone et al. 2002). Members of this pathway that commonly experience 
disruption include Fas receptor and TRAIL receptors 1 and 2 (Johnstone et al. 2002; 
Johnstone et al. 2008). Fas receptor, also known as Apo-1 or C95, is normally an 
extrinsic inducer of apoptosis and is responsible for the recruitment of the adaptor 
protein FADD and activation of membrane-proximal initiator caspases 8 and 10 
(Lowe and Lin 2000; Johnstone et al. 2002; Johnstone et al. 2008). Since the 
proteolytic cleavage of caspase 8 results in the activation of its downstream 
components (e.g. caspases 3 and 7) in the extrinsic pathway or the activation of 
intrinsic pathway member Bid, functional mutations of this death receptor increases 
a tumor cell’s resistance to apoptosis in either pathway (Johnstone et al. 2002). 
Autoimmune lymphoproliferative syndrome (ALPS) is a disorder marked by an 
inability to regulate the body’s lymphocyte population due to a Fas receptor defect. 
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In this disorder, aberrant T-lymphocytes are able to evade apoptosis, and therefore, 
the frequency of lymphoma cancers in patients with ALPS is significantly increased 
(Johnstone et al. 2002). TRAIL receptor 1, otherwise known as Apo-2, and TRAIL 
receptor 2, are, like other members of the TNF receptor superfamily, responsible for 
the induction of apoptosis following the binding of extracellular ligands (e.g. TRAIL).  
Mutations in TRAIL receptors 1 and 2 and their downstream effectors (e.g. caspases 
8 and 10) have been detected in a number of cancer types, including hematopoietic 
and breast cancers (Johnstone et al. 2008). In addition to encouraging tumorigenesis 
through the inhibition of apoptosis, alterations in extrinsic pathway death receptors 
appear to alter immune system surveillance, thereby promoting metastasis (Bold et 
al. 1997; Johnstone et al. 2002; Johnstone et al. 2008).  
   
 
Apoptosis and Cancer Therapy 
Traditional cancer therapy consists of a combination of surgery and cytotoxic 
agents, like chemotherapy and radiation. Surgery was first used to eliminate whole 
tumors, as well as lymph nodes, following the advent of anesthesia in the mid-
nineteenth century (Sudhakar 2009). Medical imaging, like ultrasound and MRI, 
were developed in the 1970s, and improved the efficacy of tumor excision by 
reducing exploratory surgery (Sudhakar 2009). The use of cytotoxic agents, in 
combination with surgery, also greatly improved the effectiveness of cancer 
treatment (Sudhakar 2009). Chemotherapy, itself, was first used in the 1940s when 
researchers studied mustard gas and compounds related to it in order to develop 
better chemical warfare, as well as to develop better treatments against it (Sak 
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2012; American Cancer Society 2014). During this time, American pharmacologists, 
Louis Goodman and Alfred Gilman, reviewed the medical records of soldiers 
exposed to mustard gas in WWI and found that many of them suffered immune cell 
reduction (Sak 2012; Hazell 2014). In 1942, Goodman and Gilman administered 
mustard gas to a patient with lymphoma, after hypothesizing that if it has the 
capability to reduce normal immune cells, it should also be able to reduce cancerous 
ones. The administration of the mustard gas was found to alleviate some of the 
patient’s discomfort (Hazell 2014). In 1948, Scottish chemist Alexander Haddow 
studied the component of mustard gas responsible for cytotoxicity and found that 
this component, called nitrogen mustard, induced cellular suicide with higher 
specificity than mustard gas (Hazell 2014). The use of radiation to treat cancer was 
discovered even earlier than chemotherapy, in 1896, when American scientist Emil 
Grubbe used radiation to treat a woman with breast cancer, and found that it briefly 
improved her condition (Markel 2015).  
 By the end of the 20th century, with more advanced surgical techniques, a 
larger variety of chemotherapeutic agents, and more precise delivery of 
chemotherapy and radiation (chemoradiation), cancer therapy had greatly 
improved (Sudhakar 2009). Traditional cancer therapies were further enhanced 
with increased understanding and evidence of the mechanisms responsible for cell 
death, as well as how these mechanisms were modified in different cancer types. 
Modern chemotherapy, therefore, came to be known as targeted cancer therapy. 
Targeted cancer therapy differs from traditional chemotherapy in that drugs, which 
can be cytostatic or cytotoxic, are designed or selected to act on specific molecular 
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targets, whereas traditional chemotherapy destroyed all cells to which it was 
administered (i.e. both healthy and cancerous cells) (National Cancer Institute 
2014). Gene therapy is also often employed, alongside targeted cancer therapy, to 
increase the effectiveness of chemotherapeutic agents or to reestablish tumor 
sensitization to them.  
Much of the current research on the relationship between apoptosis and 
cancer is concerned with the modifications in the pathways controlling apoptosis 
(e.g. p53) and how these can be utilized to improve targeted cancer and gene 
therapies (Lowe and Lin 2000). For example: Due to its involvement of p53 in 
apoptosis, many cancer treatments are concerned with targeting it with 
chemoradiation or restoring its function with gene therapy (Wang and Sun 2010).  
Traditional cancer therapies, like chemotherapy and radiation, are able to 
upregulate p53 by damaging cellular DNA and, therefore, increase apoptosis (Wang 
and Sun 2010). Since many cancer types are associated with mutations in p53, 
chemoradiation is often inappropriate and associated with drug resistance (Bold et 
al. 1997; Lowe and Lin 2000; Johnstone et al. 2002). Gene therapy allows the 
restoration of p53, and apoptosis, through viruses that reintroduce the wild-type 
allele or small molecules that bind to p53 and block the binding of its competitive 
inhibitors (Issaeva et al. 2004; Wang and Sun 2010). For instance, replication-
deficient adenovirus (Ad-p53) was successfully used to reintroduce wild-type p53 
to human lung cancer cells, and is now marketed under the brand name of 
Gendicine/Advexin for treatment of head, neck, and lung cancers (Wang and Sun 
2010). ONYX-015 is an E1B-deleted adenovirus, currently in clinical trials, that 
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selectively replicates in and lyses cancer cells that do not express functional p53 
(Wang and Sun 2010). RITA is the name of a small molecule that has been used to 
reactivate p53 by preventing the binding of Mdm2, an inhibitor of p53, as well as 
other repressors of apoptosis, including Mcl-1 and Bcl-2 (Issaeva et al. 2004; Wang 
and Sun 2010).  
 
 
Vitamins and Cancer Therapy 
The use of cancer therapies to upregulate p53 or modify its functionality, in 
order to induce apoptosis, provide evidence of the myriad possibilities that exist 
with both traditional and modern cancer treatments, as well as the challenges in 
integrating these approaches. Another emerging area of cancer research and 
integration is the use of vitamins and dietary metabolites, like vitamins C, D, E, and 
K, as primary or supplementary means of inducing apoptosis (Mathiasen et al. 1999; 
Sakagami et al. 2000; Sylvester 2007; Karasawa et al. 2013). Various types of 
vitamin K, for instance, have been shown to induce apoptosis and inhibit cell growth 
in a number of cancer types, including leukemia, lung, myeloma, and lymphoma, 
through the modification of members of both apoptotic pathways (Yaguchi et al. 
1997; Yoshida et al. 2003; Tsujioka et al. 2006; Blair and Miller 2012). Vitamin K has 
also been used to enhance the apoptotic and inhibitory effects of pre-existing anti-
cancer drugs, like Sorafenib, in pancreatic and liver cancers (Wei et al. 2010; Wei et 
al. 2010; Carr et al. 2011).  The characterization and use of organic and nutritive 
compounds (like vitamin K) to induce apoptosis and inhibit cancerous cell growth is 
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appealing because of the resulting lack of damage to healthy cells, as well as the 
benefits to the immune system and implications for prevention (Mora et al. 2008).  
 
Vitamin K. Vitamin K represents a class of fat-soluble, structurally similar 
vitamins that are known for their role as a cofactor in the post-translational 
modification (carboxylation) of proteins involved in blood coagulation and bone 
metabolism, which allows them to bind calcium ions, as well as in the regulation of 
cellular processes (Higdon 2000; Ehrlich 2013). Structurally, this group of vitamins 
is characterized by a naphthoquinone ring and a side chain consisting of 5-carbon 
units that vary in length, branching, and degree of unsaturation (Fieser et al. 1941; 
National Institute of Health 2015). There are two natural analogs of vitamin K – 
vitamin K1 (VK1) or phylloquinone and vitamin K2 or menaquinones (Higdon 
2000). Phylloquinone is a phytochemical and metabolite of photosynthesis, where it 
functions as an electron carrier during photophosphorylation in chloroplasts (Marks 
1975). Phylloquinone is primarily obtained through the dietary intake of higher 
order plants (National Institute of Health 2015). This analog of vitamin K is more 
saturated than menaquinones, containing only one double bond in its side chain, 
and is composed of the characteristic naphthoquinone ring and a four-unit side 
chain (Figure 1) (National Center for Biotechnology Information 2015). 
Menaquinones, in contrast, are a group of compounds that are synthesized by 
intestinal microbiota from animal products (i.e. meat, dairy), as well as fermented 
foods (Higdon 2000). Menaquinones consist of homologs that vary in the length of 
their unsaturated side chain and where each side chain unit contains a double bond, 
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and range from MK-2 through MK-14 (Higdon 2000; National Center for 
Biotechnology Information 2015; National Institute of Health 2015). Menaquinones 
are named according to the number of 5-carbon side chain units they contain, so 
that MK-4, for example, contains four side chain units (Higdon 2000). There are 
several types of synthetic vitamin K, with the most recognized being vitamin K3 or 
menadione (Higdon 2000; Council for Responsible Nutrition 2013). Menadione is a 
derivative of vitamin K, containing only the naphthoquinone ring, and is inactive 
until in vivo alkylation occurs (Higdon 2000; National Center for Biotechnology 
2015). Unlike phylloquinone and menaquinones, the synthetic isomers of vitamin K, 
including menadione, are associated with toxicity (e.g. allergic reactions and 
hemolytic anemia) in large doses (Council for Responsible Nutrition 2013). 
  
 
 
 
 
   
  
 
 
 
 
Phylloquinone, Apoptosis, and Cancer Therapy 
Both natural analogs of vitamin K, phylloquinone and menaquinones, as well 
as synthetic menadione, have been shown to be involved in the induction of 
Figure 1: Structure of Phylloquinone. 2d chemical structure of 
phylloquinone or vitamin K1, IUPAC: 2-methyl-3-[(2E)-3,7,11,15-
tetramethylhexadec-2-en-1-yl]napthoquinone (Source: ChemSpider). 
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apoptosis and inhibition of cancer cell growth, both in vitro and in vivo (Yaguchi et 
al. 1997; Yoshida et al. 2003; Hitomi et al. 2005; Criddle et al. 2006; Tsujioka et al. 
2006; Zhang et al. 2006; Wei et al. 2010; Wei et al. 2010; Carr et al. 2011; Zhang et 
al. 2012; Karasawa et al. 2013; Suresh et al. 2013; Linsalata et al. 2015; Orlando et 
al. 2015). The apoptotic and anti-proliferative effects of phylloquinone have been 
examined in a number of cancer types, including colon, gastric, liver, and pancreatic 
(Wei et al. 2010; Wei et al. 2010; Carr et al. 2011; Linsalata et al. 2015; Orlando et al. 
2015).  One study examined these effects of phylloquinone in three colon cancer cell 
lines and found treatment with increasing concentrations of phylloquinone (10 μM 
to 200 μM) resulted in reduced cell growth and increased rates of apoptosis 
(Orlando et al. 2015). In addition, this study found phylloquinone modified the 
proliferative Ras/Raf/MEK/ERK pathway and significantly increased the ratio of 
Bax/Bcl-2 at concentrations of 100 μM or higher (Orlando et al. 2015).  Another 
study looked at the effects of increasing concentrations of  phylloquinone (10 μM to 
200 μM) in gastric and colon cancer cell lines and found a concentration-dependent 
inhibition of cell proliferation and increased rates of apoptosis, particularly in colon 
cancer cells (Linsalata et al. 2015). This study also found decreased phosphorylation 
to members of the Ras/Raf/MEK/ERK pathway, as well as decreased polyamine 
biosynthesis, to be involved in these effects (Linsalata et al. 2015).  
Two studies examined the effects of phylloquinone in combination with 
sorafenib, a small molecule tyrosine kinase inhibitor, and found the combined use of 
these compounds significantly elevated their apoptotic and inhibitory effects in both 
human and rodent hepatocellular carcinomas, compared to the separate use of both 
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compounds (Wei et al. 2010; Carr et al. 2011). These studies found the separate use 
of phylloquinone and sorafenib decreased phosphorylation of the calcium-
dependent Ras/Raf/MEK/ERK pathway, upregulated p53, and increased the 
localization of several intrinsic inducers of apoptosis, including Bak and Bax, 
however, using these compounds together significantly enhanced their anti-cancer 
molecular modifications (Figure 2) (McCubrey et al. 2007; Wei et al. 2010; Carr et al. 
2011). In addition to synergistically increasing the anti-cancer effects of one 
another, these studies found that the dosage of sorafenib (2.5 μM) and 
phylloquinone (25 μM) could be reduced and still produce the same effects (Wei et 
al. 2010; Carr et al. 2011). Another study examined the ability of phylloquinone and 
sorafenib to induce apoptosis and inhibit cell growth, both alone and combination, 
in pancreas adenocarcinoma cell lines, and found the separate use of these 
compounds produced insignificant anti-cancer effects, but when used in 
combination, there was a strong association with apoptosis and cell growth 
inhibition (Wei et al. 2010). This study also found that the combined use of 
phylloquinone and sorafenib activated effector caspase 3, initiator caspase 8, and 
intrinsic inducer of apoptosis, Bid, as well as inhibited proliferative pathway, 
Ras/Raf/MEK/ERK (Wei et al. 2010). Lastly, this study again found that by 
combining phylloquinone and sorafenib, they could reduce the dosage of each 
compound (2.5 μM and 25 μM, respectively) and still produce the same effects (Wei 
et al. 2010). 
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These studies document the apoptotic and inhibitory effects of 
phylloquinone, whether used alone or in combination with an anti-cancer drug, and 
in doing so, demonstrate its chemotherapeutic and cytotoxic potential. There are, 
however, a fundamental lack of studies validating these effects, when compared to 
the chemotherapeutic utilization of menaquinones and menadione, and therefore, 
further characterization of phylloquinone is needed. Exploring the anti-cancer 
effects of phylloquinone could provide us with a better understanding of the 
mechanisms governing apoptosis and how tumor cells are able to modify these 
Figure 2: Members of the Intrinsic and Extrinsic Apoptotic Pathways Affected 
by Phylloquinone in Liver and Pancreatic Cancers. Some members of the 
intrinsic or mitochondrial and extrinsic or death receptor pathway that have been 
shown to be modified following treatment with phylloquinone, alone or in 
combination with Sorafenib – a small tyrosine kinase inhibitor (McCubrey et al. 
2007; Wei et al. 2010; Wei et al. 2010; Carr et al. 2011; modified from Panayi et 
al. 2013). 
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mechanisms to promote tumorigenesis and metastasis. In addition, further 
characterization of phylloquinone would help to support its ability to enhance 
apoptosis and diminish cancer cell growth, and may lead its use as an anti-cancer 
drug, alone or in combination with other regulators of these processes.  
 
 
Hypothesis, Rationale, and Specific Aims 
 
This study seeks to verify the apoptotic and inhibitory effects of 
phylloquinone in a non-Hodgkin lymphoma cell line, known as U937. Through the 
examination of preliminary data and pertinent literature, the following hypotheses 
were made: (1) Treatment with phylloquinone will increase the frequency of 
apoptosis. (2) Treatment with phylloquinone will result in U937 cells with larger 
areas, which is attributed to membrane blebbing or macrophage differentiation 
(Blair and Miller 2012). (3) Treatment with phylloquinone will have an anti-
proliferative effect on U937, resulting in decreased cell density. (4) Higher 
concentrations of phylloquinone and longer treatment times will enhance these 
effects, resulting in greater rates of apoptosis, less remaining viable U937 cells, and 
cells with even larger areas. These hypotheses are based on a preliminary study that 
was conducted in 2012, in which I a concentration-dependent reduction in U937 
was observed and attributed to the induction of apoptosis. An increase in cell area 
was also observed and attributed to an increase in membrane blebbing and 
macrophage differentiation, as a result of apoptosis (Blair and Miller 2012). These 
experiments will be replicated and modified, in order to verify the occurrence of 
apoptosis.  
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 This study will examine the ability of phylloquinone to reduce U937 cell 
growth through the induction of apoptosis in both a concentration- and time-
dependent manner, in order to better characterize its effects, as well as to establish 
an experimental protocol. The effects of phylloquinone will be assessed through the 
quantification of U937 cell density and area, as well as through the use of molecular 
markers for apoptotic cell death to both verify and quantify its occurrence. The 
results of this study will provide evidence of the anti-cancer potential of 
phylloquinone, as well as will provide insight into its effects in a non-Hodgkin 
lymphoma cell line.   
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
Experimental Design 
 
 The first aim of this study was to repeat the preliminary experiment, in order 
to verify the concentration-dependent reduction in U937 cell numbers, following 
treatment with several concentrations of phylloquinone (Blair and Miller 2012). In 
order to accomplish this, a series of experiments using the same parameters as the 
first study, such as treatment concentrations of 0, 10, 50, 100, or 500 μM 
phylloquinone and a treatment time of 7 days, were conducted (Table 1). Cell 
densities were determined for each control or treatment group. The second aim of 
this study was to establish an experimental protocol, in regards to phylloquinone 
concentration and treatment duration. This was accomplished by conducting 
several time series experiments, in which U937 densities were determined every 24 
hours for 4 days (Table 1). In addition, a narrower range of treatment 
concentrations (0, 100, or 500 μM) was selected. These experiments led to selection 
of a 48-hour treatment time, as well as the continued use of 100 or 500 μM 
phylloquinone, for all future experiments (Table 1). The third aim of this research 
was to show that phylloquinone does induce apoptosis, as well as to show that this 
type of cell death is responsible for the resulting effects on cell density and area. To 
complete this, immunofluorescence assays were utilized to label cell surface and 
nuclear markers for apoptosis, which allowed the classification of individual cells as 
'apoptotic' or 'non-apoptotic' (Table 1). Overall cell densities were determined at 
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the conclusion of each experiment. Afterwards, cells were incubated with 
fluorescently conjugated antibodies, wet mounted onto slides, and photographed. 
U937 cell areas were determined from these photographs. The fourth aim of this 
research was to demonstrate that higher concentrations of phylloquinone increase 
the frequency of apoptosis. This was completed by examining the proportion of cells 
labeled apoptotic from random field view photographs taken during 
immunofluorescence. Further details on experimental methodology and analysis are 
provided below.  
 
 
 
No. Date Duration 
(days) 
No. of 
Samples 
No. of 
Concentrations 
Description 
1 5-23-14 7 10 4 Cell Density 
2 6-9-14 7 10 4 Cell Density 
3 7-11-14 4 3 2 Cell Density, Time Series 
4 8-1-14 4 3 2 Cell Density, Time Series 
5 8-1-14 7 12 4 Cell Density 
6 9-10-14 4 3 2 Cell Density, Time Series 
7 10-1-14 2 6 2 Cell Density, Cell Area 
8 11-3-14 2 6 2 Cell Density, Cell Area 
9 2-7-15 2 12 2 Cell Density 
10 2-9-15 2 12 2 Cell Density 
11 3-10-15 2 6 2 Cell Density, Cell Area, Annexin V 
12 5-18-15 2 6 2 Cell Density, Cell Area, Annexin V 
13 8-5-15 2 6 2 Cell Density, Cell Area, APO-BrdU 
14 8-13-15 2 6 2 Cell Density 
15 8-24-15 2 6 2 Cell Density 
16 8-28-15 2 6 2 Cell Density, Cell Area, APO-BrdU 
17 9-24-15 2 6 2 Cell Density, Cell Area, APO-BrdU 
18 9-24-15 2 6 2 Cell Density, Cell Area, Annexin V 
Table 1: Experiment List. List of experiments (N = 18) containing the date, 
duration, number of samples, number of phylloquinone concentrations, and a 
description of the type of data collection – cell density, area, and/or the occurrence 
of apoptosis (i.e. annexin V or APO-BrdU). 
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U937 Cell Line and Cell Culture 
 U937 cells were provided by the American Type Culture Collection (ATCC, 
Manassas, VA, United States). U937 were isolated from a histiocytic pulmonary or 
non-Hodgkin lymphoma of a 37-year-old Caucasian male (Sundström and Nilsson 
1976; Sigma-Aldrich 2015). This non-adherent cell line exhibits the morphology of 
monocytes, but is capable of adopting the morphology of macrophages (Figure 3) 
(Passmore et al. 2001; Sigma-Aldrich 2015). U937 cells were maintained and 
cultured in RPMI-1640 with L-glutamine and sodium bicarbonate (Fisher Scientific, 
United States). Cell media was supplemented with 20% fetal bovine serum (FBS) 
(Sigma-Aldrich, United States). U937 cells were subcultured on a weekly basis at a 
1:5 ratio of cells to media for a total volume of 30 ml per culture flask. All cell 
cultures were incubated and maintained at 37°C and 5% CO2. 
 
Experimental Culture Conditions 
 Cell culture experiments were set-up with an initial cell density of 1 x 105 or 
2 x 105 cells/ml, depending on the particular experiment (Table 1). Cell stock 
densities were obtained via hemocytometer counts and adjusted to the specified 
concentration by diluting with supplemented media containing the appropriate 
concentration of phylloquinone (0, 10, 50, 100, or 500 μM). Cell media containing 
phylloquinone was diluted from a stock solution of 500 μM phylloquinone in 0.5% 
ethanol and supplemented cell media (RPMI-160 with 20% FBS) (see 
"Phylloquinone Solution", below). Cells were cultured in 12-well culture plates, with 
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a total volume of 3 ml of solution per well and incubated at 37°C and 5% CO2 for 24 
hours to 7 days, depending upon the experiment (Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phylloquinone Solution  
 A 500 μM phylloquinone stock solution was prepared by dispensing 4.6 μl 
phylloquinone (Sigma-Aldrich, United States) into 100 μl of ethanol and 2 ml of pre-
warmed media (37°C) supplemented with FBS. This solution was briefly vortexed 
and diluted to 20 ml with additional warmed media. A 7 ml aliquot of 500 μM 
phylloquinone stock was transferred to a 15 ml conical tube and stored in a water 
Figure 3: U937 cells at 20x magnification. Image of wet mount of untreated 
U937 cells at 20x magnification. The majority of the cells in this image exhibit the 
morphology of monocytes, while several exhibit the morphology of macrophages.  
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bath at 37°C until plating. Other concentrations of phylloquinone were made by 
diluting aliquots of the 500 μM stock solution to the appropriate concentration of 
phylloquinone (10, 50, or 100 μM) with 37°C supplemented media, for a total 
volume of 7 ml per each treatment concentration (Table 2). An aliquot of media 
containing 0 μM phylloquinone was created by diluting 35 μl of ethanol to 7 ml with 
pre-warmed RPMI-1640 supplemented with 20% FBS. Each aliquot was stored at 
37°C until use. 
 
 
 
   
 
Cell Culture Preparation 
 After establishing U937 cell stock density with hemocytometer counts, the 
appropriate volume of cell stock needed for 7 ml of solution with 1 x 105 or 2 x 105 
cells/ml was calculated. This volume was pipetted first from the 7 ml aliquot of 
supplemented media intended for the control U937 group and replaced with the 
same volume of U937 cell stock. The cell-media aliquot was homogenized by 
inversion and 3 ml of this solution was dispensed into each control well. This 
Phylloquinone Concentration 
(μM) 
Volume of 500 
μM Stock (ml) 
Volume of Supplemented 
Media (ml) 
0 0.00 6.97* 
10 0.14 6.86 
50 0.70 6.30 
100 1.40 5.60 
500 7.00 0.00 
Table 2: Phylloquinone Treatment Solution. Composition of 
phylloquinone solution by volume of 500 μM stock and 
supplemented media for each treatment concentration, for a total of 
7 ml per concentration. * The difference in volume in the control (0 
μM) is due to the presence of ethanol (35 μl).  
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procedure was repeated for each treatment group, until all culture wells contained 3 
ml of U937 at the calculated density, with 0, 10, 50, 100, or 500 μM phylloquinone in 
supplemented media. The U937 stock culture flask and cell-media aliquots were 
gently inverted between pipetting to ensure homogenization.  
 
Data Collection 
 
Cell Density and Area Determination 
U937 cell densities were determined at the end of each experiment using a 
hemocytometer (Figure 4). Eight counts were conducted per control or treatment 
group, and averaged. Care was taken to homogenize the culture plate before 
sampling. U937 cell areas were determined by photographing wet mounted slides of 
each group and measured using an image analysis program, called ImageJ, U.S. 
National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/. 
Cell areas were also determined following immunofluorescence assay (see 
“Determination of Apoptosis”, below). For non-assayed cell areas, four random 
bright-field images were taken at 20x magnification (Figure 4). For assayed cells, 
each image was taken twice – once using fluorescence microscopy and once using 
bright-field microscopy – in order to distinguish between apoptotic and non-
apoptotic cells. Fluorescent photographs were taken using the green excitation 
filter. The red excitation filter was also used to view the cells to ensure they were 
not auto-fluorescing. As before, four random images of each slide were taken at 20x 
magnification. Care was taken to minimize the amount of time each slide was 
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exposed to light to avoid photobleaching. Overall, apoptotic, and non-apoptotic 
U937 cells were measured and distinguished between using ImageJ. To do this, 
ImageJ was calibrated to a known distance at 20x magnification. The freehand lasso 
tool was then used to select the perimeter of each cell in an image. Overall cell areas 
were measured and analyzed by treatment group, as well as separately on the basis 
of fluorescence (where applicable), which was used as an indicator of apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Cell Density, Cell Area, and Percent Apoptosis Flowchart. Flowchart 
outlining U937 cell density, cell area, and percent apoptosis determination.  
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Determination of Apoptosis 
 
 Apoptotic U937 cells were labeled using either the Annexin V-FITC Apoptosis 
Detection Kit (Sigma-Aldrich, United States) or APO-BrdU™ TUNEL Assay Kit, with 
Alexa Fluor® 488 Anti-BrdU (Sigma-Aldrich, United States) (Figure 5). Both assays 
utilize fluorescently conjugated antibodies to visualize biochemical changes 
characteristic of apoptosis. The annexin V protein was provided as part of the 
Annexin V FITC Apoptosis Detection Kit, which labels phosphatidylserine residues 
with annexin V conjugated to Alexa Fluor® 488. Phosphatidylserine is a 
phospholipid that is translocated from the inner-to-outer cell membrane early on in 
apoptosis. Annexin V has a high binding affinity for phosphatidylserine and binds to 
it preferentially, emitting fluorescence at the cell's surface that is detectable under 
UV light (van Engeland et al. 1998). The BrdUTP substrate and antibody were 
supplied with the APO-BrdU™ TUNEL Assay Kit. BrdUTP is a substrate that binds to 
3'-hydroxyl ends of DNA, which are exposed following fragmentation in late stage 
apoptosis. The anti-BrdU anti-body included in this kit is fluorescently labeled with 
Alexa Fluor® 488 and binds to BrdUTP with high affinity, emitting nuclear 
fluorescence that is detectable under UV light (ThermoFisher Scientific 2015).  
 
 
Annexin V Assay. The Annexin V-FITC Apoptosis Detection Kit was used to 
label apoptotic cells according to the following procedure (Figure 5). Following cell 
density determination, the contents of each well were collected and dispensed into 
separate 15 ml conical tubes. Each well of the culture plate was rinsed with 3 ml of 
cold (4°C) phosphate-buffered saline (PBS) and this was also dispensed into the 
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appropriate tube. These were centrifuged at 1000 rpm for 5 minutes. Once pelleted, 
the supernatant was poured off and the cells were washed in 1 ml of cold PBS, 
transferred to 1.5 ml microcentrifuge tubes, and re-pelleted by centrifugation at 
1000 rpm for 5 minutes. The Annexin V Incubation Reagent was prepared by 
combining 10 μl of 10X Binding Buffer, 1 μl of Annexin-V conjugate, and 79 μl of 
deionized water, per cell sample. Care was taken to minimize reagent light exposure, 
and all components were stored on ice. Each sample was resuspended in 90 μl of 
reagent and incubated in the dark for 15 minutes at room temperature. The samples 
were then centrifuged for 5 minutes at 1000 rpm, pelleted, and washed with room 
temperature 0.5 ml 1X Binding Buffer, which was diluted from 10X Binding Buffer 
with deionized water. Following centrifugation, cells were resuspended in 100 μl of 
Binding Buffer and separately wet mounted to glass microscope slides. Glass 
coverslips were applied and slides were allowed to sit for several minutes before 
being transferred to the microscope. Samples were viewed and photographed 
within 2 hours.   
 
 
APO-BrdU Assay. The APO-BrdU™ TUNEL Assay Kit was used to label 
apoptotic cells according to the following procedure (Figure 5). Following density 
determination, the contents of each well were collected as described above 
(“Annexin V Assay”). The samples were centrifuged at 1000 rpm for 5 minutes and 
resuspended in 5 ml of 1% paraformaldehyde (PFA) in PBS. Cells were fixed on ice 
for 5 minutes. The samples were then centrifuged for 5 minutes at 1000 rpm and 
washed in 5 ml of cold (4°C) PBS. This wash was repeated and each sample was 
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resuspended in 0.5 ml of PBS. To each test tube, 5 ml of ice-cold 70% ethanol was 
added. Cells were stored overnight at -20°C. The following day, the samples were 
allowed to come to room temperature and centrifuged at 1000 rpm for 5 minutes. 
Each sample was resuspended in 1 ml of wash buffer, transferred to 1.5 ml 
microcentrifuge tubes, and centrifuged at 1000 rpm for 5 minutes. This wash was 
repeated. The DNA-labeling solution was prepared by combining 10 μl of reaction 
buffer, 0.75 μl of TdT enzyme, 8.0 μl of BrdUTP, and 31.25 μl of deionized water, per 
cell sample.  Each sample was resuspended in 50 μl of this solution and incubated 
for 60 minutes in a water bath at 37°C. Care was taken to invert the samples every 
15 minutes, in order to keep the cells in suspension. Following incubation, 1 ml of 
rinse buffer was added to each sample and these were centrifuged at 1000 rpm for 5 
minutes. This wash was repeated. The antibody staining solution was prepared by 
combining 5.0 μl Alexa Fluor® 488 dye-labeled anti-BrdU antibody with 95 μl of 
rinse buffer, per cell sample. Care was taken to minimize reagent light exposure, and 
all components were stored on ice. Each sample was resuspended in 100 μl of this 
solution and incubated for 30 minutes in the dark at room temperature. Following 
incubation, the contents of each tube were wet mounted to glass microscope slides. 
Glass coverslips were applied and slides were allowed to sit for several minutes 
before being transferred to the microscope. Samples were viewed and 
photographed within 2 hours.  
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Figure 5: Annexin V and APO-BrdU Assay Flowchart. Flowchart outlining the 
annexin V and APO-BrdU assay binding protocols used for these experiments.  
APO-BrdU 
Assay 
 
Annexin 
V Assay 
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Analysis 
 
Occurrence of Apoptosis Analysis 
The occurrence of apoptosis was determined as a percent (Table 3). Percent 
apoptosis was calculated as the number of cells labeled with annexin V or APO-
BrdU, relative to the total number of assayed cells, by treatment group. 
 
 
Cell Area Analysis 
 GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla, 
California, USA, www.graphpad.com and IBM SPSS software were used to analyze 
cell area data and create cell area figures (Figures 9 - 19). Cell areas were analyzed 
by treatment concentration, as well as between apoptotic or non-apoptotic groups, 
using a one-way analysis of variance (ANOVA). A one-way ANOVA was selected to 
test whether there is a significant difference between the variances of cell area 
(dependent variable) by treatment concentration (independent variable). 
 
 
Cell Density Analysis 
GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla, 
California, USA, www.graphpad.com, Minitab, and IBM SPSS software were used to 
obtain statistics and create cell density figures (Figures 20 – 26). Cell densities were 
analyzed by treatment concentration and/or time, using a one- or two-way analysis 
of variance (ANOVA). A one-way ANOVA was selected to test whether there is a 
significant difference between the variances of cell density (dependent variable) by 
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treatment group (independent variable). A two-way ANOVA was selected to test 
whether there is a significant difference between the variances of cell density 
(dependent variable) by treatment concentration and time (independent variables).   
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CHAPTER 3 
 
RESULTS 
 
 
 
Occurrence of Apoptosis 
 
The occurrence of apoptosis was determined for all assayed cells, following 
treatment with 0, 100, or 500 μM phylloquinone for 48 hours (Table 3). Apoptosis 
was examined as a percent. Percent apoptosis was calculated from the number of 
cells binding annexin V or APO-BrdU relative to the total number of assayed cells for 
that treatment group. The percent apoptosis for cells treated with 100 or 500 μM 
phylloquinone is 49.7% and 60.6%, respectively, while 8.5% of cells treated with no 
phylloquinone underwent apoptosis. This analysis also shows a concentration-
dependent increase in the induction of apoptosis with increasing concentrations of 
phylloquinone, however, the rates of apoptosis increased by only about 10% with a 
fivefold increase in the concentration of phylloquinone. These results are based 
upon six experimental replicates, with three of each assay type (Annexin V or APO-
BrdU) (Table 1).  
 Images of U937 cells treated with 0, 100, and 500 μM phylloquinone labeled 
with annexin V are shown below (Figure 6). Cells that are fluorescent, or positive for 
the binding of annexin V, are considered to be in the early stages of apoptosis. These 
images show treatment with 100 μM phylloquinone increases the frequency and 
intensity of the binding of annexin V, as well as reduces cell density and increases 
cell area. These images also show treatment with 500 μM phylloquinone enhances 
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these effects, resulting in higher and more intense binding of annexin V and even 
less remaining U937 cells with larger areas.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phylloquinone 
Concentration 
(μM) 
No. of annexin 
V binding cells 
No. of APO-
BrdU binding 
cells 
Total number of 
apoptotic cells 
Total 
number of 
cells 
Percent 
apoptosis 
0 17 57 74 867 8.5% 
100 297 129 426 858 49.7% 
500 309 219 528 871 60.6% 
Table 3: Occurrence of Apoptosis Following Treatment with 0, 100, or 500 μM 
Phylloquinone for 48 Hours. Percent apoptosis determined from the number of 
U937 cells binding annexin V or APO-BrdU relative to the total number of U937 by 
treatment concentration. Table contains number of annexin V or APO-BrdU binding 
U937 cells, as well as the total number of apoptotic cells, total number of measured 
cells, and percent apoptosis, following treatment with phylloquinone (0, 100, or 500 
μM) at 48 hrs. Table represents the results of six different experiments (N=6).  
Figure 6: U937 Cells Binding Annexin V Following Treatment with 0, 100, or 
500 μM Phylloquinone for 48 Hours. Images of U937 cells at 20x magnification 
following treatment with increasing concentrations of phylloquinone (0, 100 or 
500 μM) at 48 hrs. Apoptotic cells are labeled with annexin V conjugated to Alexa 
Fluor 488.  
 
0 μM phylloquinone 100 μM phylloquinone 500 μM phylloquinone 
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Cell Area 
 
 U937 cell areas were determined following treatment with 0, 100, or 500 μM 
phylloquinone for 48 hours (Figure 7, Table 1). Cell areas were analyzed on the 
basis of phylloquinone concentration, by apoptotic and non-apoptotic groups, and 
by assay type (i.e. Annexin V or APO-BrdU). Overall cell areas were determined from 
all experiments where cell areas were collected, without regard to apoptotic or non-
apoptotic groups, and show a concentration-dependent increase in mean cell area 
following treatment with increasing concentrations of phylloquinone (Figure 7). The 
mean cell area of cells treated with no phylloquinone is 0.162 μm2, while the mean 
cell areas of cells treated with 100 or 500 μM phylloquinone are 0.173 μm2 and 
0.199 μm2, respectively. This data represents the results of eight experimental 
replicates. This data were analyzed using a one-way ANOVA. The results of this 
analysis indicate overall U937 area varies significantly between control and 
treatment groups, and increases with increasing phylloquinone concentrations (F 
(2, 3020) = 12.994, p < 0.001).  
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The distribution of all U937 cell areas is unimodal and positively skewed, 
with areas ranging from 0.0 to 2.0 μm2 (Figure 8). This distribution shows the 
majority of cells have areas that are concentrated to the left, with several outliers at 
2.0 μm2. The distribution of cell areas are shown for each concentration of 
phylloquinone (0, 100, or 500 μM) and these follow the same trend as mean cell 
area, in that, cells treated with phylloquinone are larger and occupy an area nearer 
to the right of the distribution, while untreated or control cells are smaller and 
occupy an area to the left of the distribution. In addition, cells treated with a higher 
concentration of phylloquinone (500 μM) have areas that are larger than cells 
Figure 7: Mean Cell Area Following Treatment with 0, 100, or 500 μM 
Phylloquinone for 48 Hours. Mean U937 cell area following treatment with 
increasing concentrations of phylloquinone (0, 100 or 500 μM) at 48 hrs. Data 
represents the results of eight different experiments (N = 8) (mean ± SEM). Data 
were analyzed by a one-way ANOVA (F (2, 3020) = 12.994, p < 0.001). 
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treated with a lower concentration of phylloquinone (100 μM). The range of cell 
area also varies between each group, with untreated cells exhibiting the most 
narrow spread (0.02 to 0.45 μm2), and cells treated with the higher phylloquinone 
concentrations exhibiting progressively wider ones - 0.03 to 0.61 μm2 for 100 μM 
phylloquinone and 0.04 to 2.0 μm2 for 500 μM phylloquinone. This data represents 
the results of eight experimental replicates and indicates increasing concentrations 
of phylloquinone result in cells with larger areas.  
 
 
 
 
 
 
 
 
L 
 
 
 
 
 
 
 
 
Figure 8: Distribution of Cell Area Following Treatment with 0, 100, or 500 
μM Phylloquinone for 48 Hours. Distribution of U937 cell area following 
treatment with increasing concentrations of phylloquinone (0, 100, or 500 μM) at 
48 hrs. Data represents the results of eight different experiments (N = 8). 
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U937 cell areas were also determined for both apoptotic and non-apoptotic 
cells following treatment with 0, 100, or 500 μM phylloquinone at 48 hours (Figures 
9 - 19). Cells that were identified as apoptotic due to their binding of annexin V 
exhibit a concentration-dependent increase in cell area with increasing 
concentrations of phylloquinone, so that untreated apoptotic cells have the smallest 
mean area (0.091 μm2), cells treated with a lower concentration of phylloquinone 
(100 μM) have the second largest mean area (0.098 μm2), and cells treated with a 
higher concentration of phylloquinone (500 μM) have the largest mean area (0.108 
μm2) (Figure 9). This data represents the results of three experimental replicates. A 
one-way ANOVA was used to analyze mean areas of annexin V binding cells by 
treatment group. The results of this analysis indicate there is a significant difference 
between the mean areas of untreated and treated groups of early apoptotic U937 
cells, as well as shows that the mean area of apoptotic U937 cells increases with 
increasing concentrations of phylloquinone (F (2, 620) = 4.069, p < 0.05).  
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The distribution of cells binding annexin V is unimodal and skewed to the 
right, with the majority of cell areas occupying the left of the distribution and areas 
that range from 0.04 to 0.40 μm2 (Figure 10). Cells area distributions are shown 
relative to each concentration of phylloquinone (0, 100, or 500 μM) and follow the 
same pattern as overall cell areas, in that, with increasing concentrations of 
phylloquinone, the areas of early-stage apoptotic cells increase. The distribution of 
annexin V binding cells shows that untreated cells are the least frequent and have 
the smallest areas, while annexin V binding cells treated with 100 μM phylloquinone 
are more frequent and have larger areas, and cells treated with 500 μM 
Figure 9: Mean Area of Annexin V Binding Cells Following Treatment with 0, 
100, or 500 μM Phylloquinone for 48 Hours. Mean area of annexin V binding 
U937 cells following treatment with increasing concentrations of phylloquinone (0, 
100 or 500 μM) at 48 hrs. Data represents the results of three different experiments 
(N = 3) (mean ± SEM). Data were analyzed by a one-way ANOVA (F (2, 620) = 
4.069, p < 0.05). 
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phylloquinone are the most frequent and have the largest areas. The range of 
annexin V binding cell areas also varies between treatment group, so that cells 
treated with 0 μM phylloquinone have the most narrow spread (0.05 to 0.12 μm2), 
while cells treated with 100 μM have a wider range (0.04 to 0.22 μm2) and cells 
treated with 500 μM have the widest range (0.05 to 0.40 μm2). This data represents 
the results of three experimental replicates and indicates early-stage apoptotic cells 
have larger areas with increasing concentrations of phylloquinone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Distribution of Annexin V Binding Cell Area Following Treatment 
with 0, 100, or 500 μM Phylloquinone for 48 Hours. Distribution of annexin V 
binding U937 cell area following treatment with increasing concentrations of 
phylloquinone (0, 100, or 500 μM) at 48 hrs. Data represents the results of three 
different experiments (N = 3). 
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U937 cells that did not bind annexin V, and were thus identified as non-
apoptotic, also increase in response to treatment with phylloquinone, as well as 
exhibit a concentration-dependent increase in cell area following treatment with 
higher phylloquinone concentrations (Figure 11). Mean cell areas reveal that non-
apoptotic U937 cells treated with 0 μM phylloquinone have the smallest mean area 
(0.116 μm2), while cells treated with 100 and 500 μM have larger areas (0.145 and 
0.151 μm2, respectively). This data was collected from three experimental 
replicates. A one-way ANOVA was used to analyze mean area of non-apoptotic U937 
following treatment with phylloquinone. The results of this analysis suggest there is 
a significant difference between the mean area of non-apoptotic U937 cells treated 
with different concentrations of phylloquinone (F (2, 1004) = 18.124, p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The distribution of areas of U937 cells which did not bind annexin V, and 
were thus considered non-apoptotic, is unimodal and right-skewed, with areas 
ranging from 0.02 to 1.0 μm2 (Figure 12). Again, the majority of areas are 
concentrated to the left of the distribution, with the areas of untreated cells confined 
to this region and the areas of cells treated with higher concentrations of 
phylloquinone progressing toward the right side of the distribution. In other words, 
this data follows the same trend established by preceding data, which is: the area of 
non-apoptotic U937 cells increases in the presence of phylloquinone, and is 
dependent upon concentration, so that higher concentrations of phylloquinone 
Figure 11: Mean Area of Annexin V Non-Binding Cells Following Treatment 
with 0, 100, or 500 μM Phylloquinone for 48 Hours. Mean area of annexin V 
non-binding U937 cells following treatment with increasing concentrations of 
phylloquinone (0, 100 or 500 μM) at 48 hrs. Data represents the results of three 
different experiments (N = 3) (mean ± SEM). Data were analyzed by a one-way 
ANOVA (F (2, 1004) = 18.124, p < 0.001). 
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further increase cell area. The distribution of non-annexin V binding cell areas also 
shows that while cells treated with the lower concentration of phylloquinone (100 
μM) occupy a region that is further left in the distribution than cells treated with the 
higher concentration of phylloquinone (500 μM), however, the spread of cell area 
for the lower concentration is more variable. Cell areas of non-apoptotic U937 
treated with no phylloquinone range from 0.02 to 0.60 μm2, while those treated 
with 100 μM phylloquinone range from 0.03 to 1.0 μm2 and 0.04 to 0.51 μm2 for 500 
μM. This data represents the represents the results of three experimental replicates, 
and shows that non-apoptotic cell area increases with exposure to phylloquinone, as 
well as increases in response to higher phylloquinone concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Distribution of Annexin V Non-Binding Cell Area Following 
Treatment with 0, 100, or 500 μM Phylloquinone for 48 Hours. Distribution of 
annexin V non-binding U937 cell area following treatment with increasing 
concentrations of phylloquinone (0, 100, or 500 μM) at 48 hrs. Data represents the 
results of three different experiments (N = 3). 
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U937 cell areas of cells that were identified as apoptotic based upon their 
binding of APO-BrdU demonstrate the same trend in the relationship between cell 
area and phylloquinone concentration, in that, the mean area of late-stage apoptotic 
cells increase in following treatment with phylloquinone, as well as further increase 
with increasing phylloquinone concentrations (Figure 13). The mean area of 
apoptotic control cells (0 μM) is the smallest (0.258 μm2), while apoptotic cells 
treated with 100 μM have a larger mean area (0.270 μm2), and cells treated with 
500 μM phylloquinone have the largest mean area (0.414 μm2). This data represents 
the results of three experimental replicates. A one-way ANOVA was used to analyze 
mean areas of APO-BrdU binding cells by phylloquinone concentration (0, 100, or 
500 μM). The results of this analysis indicate treatment of U937 cells with 
phylloquinone increases apoptotic cell area, as well as that apoptotic cell area is 
dependent on the concentration of phylloquinone, so that increasing the treatment 
concentration results in increasing cell areas (F (2, 402) = 14.390, p < 0.001).  
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The distribution of U937 binding APO-BrdU cell area is unimodal and 
positively skewed, with the majority of cell areas occupying the left side of the 
distribution, while several outliers are represented to the right (Figure 14). The 
distribution of APO-BrdU binding cell areas range from 0.10 to 1.90 μm2, and are 
shown for each phylloquinone concentration (0, 100, or 500 μM). Again, the 
distribution of APO-BrdU binding cells follows the same pattern as other datasets, in 
that untreated (0 μM) U937 cells are less frequent and have smaller areas (0.13 to 
0.39 μm2), while cells treated with the lower concentration of phylloquinone (100 
μM) are more frequent and have larger areas (0.10 to 1.90 μm2), and cells treated 
with the highest concentration of phylloquinone (500 μM) are the most frequent 
Figure 13: Mean Area of APO-BrdU Binding Cells Following Treatment with 0, 
100, or 500 μM Phylloquinone for 48 Hours. Mean area of APO-BrdU binding 
U937 cells following treatment with increasing concentrations of phylloquinone (0, 
100 or 500 μM) at 48 hrs. Data represents the results of three different experiments 
(N = 3) (mean ± SEM). Data were analyzed by a one-way ANOVA (F (2, 402) = 
14.390, p < 0.001). 
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and have the largest cell areas (0.10 to 1.90 μm2). It is important to note that the 
range of apoptotic cell areas for U937 treated with the lower concentration of 
phylloquinone contains both the smallest and largest areas, meaning that, although 
the majority of apoptotic cells in this treatment group exhibit areas that are larger 
than the control and smaller than the highest treatment concentration, this group 
does contain a fair amount of variability. This data represents the results of three 
experimental replicates and indicates late-stage apoptotic cells are larger when 
treated with phylloquinone, as well as that their areas increase with increasing 
concentrations of phylloquinone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Distribution of APO-BrdU Binding Cell Area Following Treatment 
with 0, 100, or 500 μM Phylloquinone for 48 Hours. Distribution of APO-BrdU 
binding U937 cell area following treatment with increasing concentrations of 
phylloquinone (0, 100, or 500 μM) at 48 hrs. Data represents the results of three 
different experiments (N = 3). 
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U937 cells that did not bind to APO-BrdU, and were thus considered to be 
non-apoptotic, once again demonstrate the same increase in area, following 
treatment with increasing concentrations of phylloquinone (Figure 15). The mean 
cell area of non-apoptotic U937 treated with no phylloquinone is the smallest (0.237 
μm2), while the mean area of cells treated with 100 μM phylloquinone is the second 
largest (0.250 μm2), and lastly, the mean area of cells treated with 500 μM 
phylloquinone is the largest (0.355 μm2). This was collected from three 
experimental replicates. A one-way ANOVA was used to analyze the mean areas of 
APO-BrdU non-binding cells. The results of this analysis indicate there is a 
significant difference between the mean cell areas of each treatment group (F (2, 
558) = 31.082, p < 0.001). 
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The distribution of APO-BrdU non-binding U937 cell area is unimodal and 
skewed to the right, with the mass of cell areas occupying the left side of the 
distribution (Figure 16). The distribution of cell areas of APO-BrdU non-binding 
cells range from 0.01 to 0.89 μm2, and are shown for each concentration of 
phylloquinone (0, 100, or 500 μM). This distribution conforms to other area 
distributions, in that the presence of phylloquinone produces non-apoptotic cells 
with larger areas, as well as that increasing concentrations of phylloquinone result 
in cells with increasingly larger areas. As before, untreated cells are the most 
frequent and occupy the left-most area of the distribution (0.01 to 0.47 μm2), while 
Figure 15: Mean Area of APO-BrdU Non-Binding Cells Following Treatment 
with 0, 100, or 500 μM Phylloquinone for 48 Hours. Mean area of APO-BrdU 
non-binding U937 cells following treatment with increasing concentrations of 
phylloquinone (0, 100 or 500 μM) at 48 hrs. Data represents the results of three 
different experiments (N = 3) (mean ± SEM). Data were analyzed by a one-way 
ANOVA (F (2, 558) = 31.082, p < 0.001). 
 
 62 
cells treated with 100 μM phylloquinone are less frequent and occupy an area of the 
distribution that is more toward the right (0.01 to 0.51 μm2) and cells treated with 
500 μM phylloquinone are the least frequent and occupy an area of the distribution 
that is furthest right (0.03 to 0.89 μm2). Like most other area distributions, 
treatment with the highest concentration of phylloquinone result in cell areas with 
the greatest spread, while untreated cells exhibit the least amount of variation in 
cell area. This data represents the results of three experimental replicates and again 
demonstrates that treatment with phylloquinone increases cell area, regardless of a 
cell’s apoptotic state. In addition, this data also shows that increasing the 
concentration of phylloquinone results in U937 cells with increasing area. 
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The distribution of both annexin V and APO-BrdU binding cell area, which 
were identified as apoptotic, is unimodal and positively skewed, with the majority of 
cell areas binding annexin V occupying the left side of the distribution and the 
majority of cell areas binding APO-BrdU occupying the right side of the distribution 
(Figure 17). This distribution suggests early-stage apoptotic cells, bound to annexin 
V, have smaller cell areas than late-stage apoptotic cells, bound to APO-BrdU. In 
addition, the spread of annexin V binding cell areas is narrower than the spread of 
Figure 16: Distribution of APO-BrdU Non-Binding Cell Area Following 
Treatment with 0, 100, or 500 μM Phylloquinone for 48 Hours. Distribution of 
APO-BrdU non-binding U937 cell area following treatment with increasing 
concentrations of phylloquinone (0, 100, or 500 μM) at 48 hrs. Data represents the 
results of three different experiments (N = 3). 
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APO-BrdU binding cells, which indicates cells experiencing apoptosis vary less in 
size in during early apoptosis and more during late-stage.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The distribution of both annexin V and APO-BrdU non-binding cell area is 
also unimodal and skewed to the right, with the majority of non-apoptotic cells 
occupying the left region of the distribution (Figure 18). This distribution indicates a 
difference between non-apoptotic U937 in the presence of annexin V or APO-BrdU, 
with those not bound to annexin V generally exhibiting smaller cell areas and those 
not bound to APO-BrdU exhibiting larger ones. The spread of cell area by assay type, 
Figure 17: Distribution of Annexin V and APO-BrdU Binding Cell Area 
Following Treatment with 0, 100, or 500 μM Phylloquinone for 48 Hours. 
Distribution of annexin V and APO-BrdU binding U937 cell area following 
treatment with increasing concentrations of phylloquinone (0, 100, or 500 μM) at 
48 hrs. Data represents the results of six different experiments (N = 6). 
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however, is more consistent, with both annexin V and APO-BrdU cells exhibiting 
similar ranges in cell area. This data suggests that although there is some difference 
between cell areas of non-apoptotic U937 in the presence of either annexin V or 
APO-BrdU, non-apoptotic cell area is less variable than apoptotic area.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The distribution of all assayed cells is also unimodal and skewed to the right, 
with the majority of all apoptotic and non-apoptotic U937 cell areas occupying the 
left side of the distribution (Figure 19). Apoptotic and non-apoptotic cells are 
Figure 18: Distribution of Annexin V and APO-BrdU Non-Binding Cell Area 
Following Treatment with 0, 100, or 500 μM Phylloquinone for 48 Hours. 
Distribution of annexin V and APO-BrdU non-binding U937 cell area following 
treatment with increasing concentrations of phylloquinone (0, 100, or 500 μM) at 
48 hrs. Data represents the results of six different experiments (N = 6). 
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represented by their binding or non-binding of annexin V or APO-BrdU. The 
distribution of all assayed cells is consistent with the distribution of overall cell area 
and is comprised of areas ranging from 0.02 to 1.90 μm2. The areas of cells binding 
annexin V appear to be generally smaller than cells not binding annexin V, while 
areas of cells binding APO-BrdU appear to be generally larger than cells not binding 
APO-BrdU. In other words, early-stage apoptotic U937 cells exhibit smaller areas 
than non-apoptotic ones, while late-stage apoptotic U937 cells have larger areas 
than non-apoptotic ones. In addition, cells binding APO-BrdU appear to have the 
greatest spread, indicating the areas of late-stage apoptotic U937 are the most 
variable.  
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Cell Density 
 
U937 cell densities were determined following various concentrations and 
experimental durations, consisting of 0, 10, 50, 100, and 500 μM phylloquinone and 
24 hours to 7 days, depending on the particular experiment (Table 1). Cell densities 
analyzed by phylloquinone concentration were divided into groups based on 
experimental duration, which consist of 48 hours (Figure 20) or 7 days (Figures 21 
and 22), in addition to 96 hour time course experiments (Figures 23-26). Initial cell 
Figure 19: Distribution of Annexin V and APO-BrdU Binding and Non-Binding 
Cell Area Following Treatment with 0, 100, or 500 μM Phylloquinone for 48 
Hours. Distribution of annexin V and APO-BrdU binding and non-binding U937 cell 
area following treatment with increasing concentrations of phylloquinone (0, 100, 
or 500 μM) at 48 hrs. Data represents the results of six different experiments (N = 
6). 
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densities were also measured, in order to ensure plating homogeneity (Figure 27). 
Mean cell density following treatment with 0, 100, or 500 μM phylloquinone for 48 
hours exhibits a concentration-dependent reduction in cell density, so that cells 
treated with 500 μM phylloquinone contain the least amount of viable cells, while 
cell treated with 0 μM phylloquinone contain the most (Figure 20). Mean cell 
densities are approximately: 297,000 cells/ml for 0 μM phylloquinone, 211,000 
cells/ml for 100 μM phylloquinone, and 117,000 cells/ml for 500 μM phylloquinone. 
This data was collected from twelve experimental replicates, with initial cell 
densities of 200,000 cells per ml of suspension. A one-way ANOVA was used to 
analyze mean cell density following treatment with 100 or 500 μM phylloquinone at 
48 hours. The results of this analysis indicate there are significantly different 
densities between control and treatment groups at 48 hours of treatment, as well as 
that increasing concentrations of phylloquinone further inhibit U937 cell growth (F 
(2, 141) = 48.086, p < 0.001).  
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Mean cell density following treatment with 0, 10, 50, 100, or 500 μM 
phylloquinone at 7 days also exhibits a concentration-dependent reduction in U937 
cell numbers, with the highest amount of remaining viable cells in the control group 
and the least amount remaining in the higher treatment concentration groups (100 
or 500 μM phylloquinone) (Figure 21). Mean cell densities for each treatment group 
are approximately: 305,000 cells/ml for 0 μM phylloquinone, 196,000 cells/ml for 
10 μM phylloquinone, 140,000 cells/ml for 50 μM phylloquinone, 94,000 cells/ml 
for 100 μM phylloquinone, and 95,000 cells/ml for 500 μM phylloquinone. These 
results vary from the 48 hour density analysis, in that the highest treatment 
Figure 20: Mean Cell Density Following Treatment with 0, 100, or 500 μM 
Phylloquinone for 48 Hours. Mean density of U937 cells following treatment with 
increasing concentrations of phylloquinone (0, 100 or 500 μM) at 48 hrs. Data 
represents the results of twelve different experiments (N = 12) (mean ± SEM). Data 
were analyzed by a one-way ANOVA (F (2, 141) = 48.086, p < 0.001). 
 
 70 
concentrations yielded cell densities that were close to one another, with a slightly 
higher reduction of U937 cells treated with 100 μM phylloquinone. This data 
represents the results of three experimental replicates with initial cell densities of 
200,000 cells/ml. A one-way ANOVA was used to analyze mean cell density 
following treatment with 100 or 500 μM phylloquinone at 7 days. The results of this 
analysis suggest mean cell densities vary significantly between treatment groups at 
7 days of treatment through a concentration-dependent inhibition of cell growth (F 
(4, 57) = 4.417, p < 0.005).  
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 21: Mean Cell Density Following Treatment with 0, 10, 50, 100, or 500 
μM Phylloquinone for 7 days. Mean density of U937 cells following treatment 
with increasing concentrations of phylloquinone (0, 10, 50, 100 or 500 μM) at 7 
days. Data represents the results of three different experiments (N = 3) (mean ± 
SEM). Data were analyzed by a one-way ANOVA (F (4, 57) = 4.417, p < 0.005). 
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One replicate of this 7 day study was presented as a separate figure due to its 
variability from other experimental results (Figure 22). A one-way ANOVA was used 
to analyze this experiment. The results of this analysis indicate cell densities are 
significantly different between treatment groups, although the relationship between 
phylloquinone concentration and cell density varies considerably from other 
experimental replicates (F (4, 17) = 4.218, p < 0.005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time course experiments consisted of treatment with 0, 100, or 500 μM 
phylloquinone for 96 hours, with cell counts conducted every 24 hours. These 
Figure 22: Abnormal Mean Cell Density Following Treatment with 0, 10, 50, 
100, or 500 μM Phylloquinone for 7 days. Mean density of U937 cells following 
treatment with increasing concentrations of phylloquinone (0, 10, 50, 100 or 500 
μM) at 7 days. Data represents the results of one experiment (N = 1) (mean ± SEM). 
Data was analyzed by a one-way ANOVA (F (4, 17) = 4.218, p < 0.005). 
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experiments exhibited both a concentration- and time-dependent reduction in 
viable U937 cells treated with 100 or 500 μM phylloquinone, while untreated U937 
cells density increased over time (Figure 23). Following 24 hours of treatment, cells 
cultured in 0 μM phylloquinone have the highest mean density, while cells treated 
with 500 μM have the lowest. This relationship is maintained and enhanced over 
time, so that at 96 hours of treatment, U937 cells treated with no phylloquinone 
have densities that are higher than both other treatment concentrations (100 μM or 
500 μM), as well as higher for the same group on previous days (24, 48, and 72 
hours). The treated groups exhibit the inverse of this trend, with the largest 
reduction of U937 cell densities in groups treated with 500 μM phylloquinone for 96 
hours, when compared to other concentrations of phylloquinone (0 or 100 μM) and 
other days (24, 48, and 72 hours). This data represents the results of three 
experimental replicates with initial densities of 100,000 cells/ml. A two-way ANOVA 
was conducted on cell densities following treatment with 100 or 500 μM at 24, 48, 
72, and 96 hours. The results of this analysis suggest mean cell area is significantly 
different between treatment concentrations and over time, and that phylloquinone 
is able to exert both a concentration- and time-dependent inhibition of U937 cell 
growth (F (6, 141) = 6.759, p < 0.001). The two-way ANOVA was also used to 
generate two line graphs depicting estimated marginal means of cell density over 
time or by phylloquinone concentration, which again depict its concentration and 
time-dependent effects (Figures 24 and 25).  
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Figure 23: Mean Cell Density Following Treatment with 0, 100, or 500 μM 
Phylloquinone for 24, 48, 72, or 96 Hours. Mean density of U937 cells following 
treatment with increasing concentrations of phylloquinone (0, 100 or 500 μM) at 
24, 48, 72, or 96 hrs. Data represents the results of three different experiments (N = 
3) (mean ± SEM). Data was analyzed by a two-way ANOVA (F (6, 141) = 6.759, p < 
0.001). 
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Figure 24: Estimated Marginal Means of Cell Density Following Treatment 
with 0, 100, or 500 μM Phylloquinone Over Time (24, 48, 72, or 96 Hours). 
Estimated marginal means of U937 cell density following treatment with 
increasing concentrations of phylloquinone (0, 100 or 500 μM) over time (24, 48, 
72, or 96 hrs). Data represents the results of three different experiments (N = 3).  
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U937 cell densities were also examined prior to treatment with 
phylloquinone to ensure both sample and replicate homogeneity, and were analyzed 
for 0, 100, or 500 μM phylloquinone (Figure 26). This data represents the results of 
four experimental replicates, where initial cell densities were projected at 200,000 
cells/ml. It appears that each sample had a mean initial density of slightly over this 
amount (approximately 231,000 cells/ml for 0 μM phylloquinone, 234,000 cells/ml 
for 100 μM phylloquinone, and 230,000 cells/ml for 500 μM phylloquinone). A one-
way ANOVA was conducted on mean cell density prior to treatment with 
Figure 25: Estimated Marginal Means of Cell Density By Phylloquinone 
Treatment Concentration (0, 100, or 500 μM) for 24, 48, 72, or 96 Hours. 
Estimated marginal means of U937 cell density by phylloquinone treatment 
concentration (0, 100 or 500 μM) for 24, 48, 72, or 96 hrs. Data represents the 
results of three different experiments (N = 3).  
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phylloquinone. The results of this analysis show initial cell density does not 
significantly vary between control and treatment groups, as well as shows that cells 
were sufficiently homogenized before plating (F (2, 21) = 0.031, p = 0.97).  
 
 
 
 
 
 
 
 
 
 
  
Figure 26: Mean Cell Density Prior to Treatment with 0, 100, or 500 μM 
Phylloquinone for 48 Hours. Mean initial U937 cell density prior to treatment 
with increasing concentrations of phylloquinone (0, 100 or 500 μM) at 48 hrs. Data 
represents the results of four different experiments (N = 4) (mean ± SEM). Data 
were analyzed by a one-way ANOVA (F (2, 21) = 0.031, p = 0.97). 
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CHAPTER 4 
DISCUSSION 
 
The Frequency of Apoptosis is Significantly Higher in U937 Cell Populations, Following 
Treatment with Phylloquinone 
 Percent apoptosis data indicate treatment of U937 cells with phylloquinone 
results in the induction of apoptosis, as well as higher concentrations of 
phylloquinone increase the frequency of apoptosis. Approximately 10% of 
untreated U937 cells underwent apoptosis, while 50% of cells treated with 100 μM 
phylloquinone and 60% of cells treated with 500 μM underwent apoptosis (Table 
3). Although there is a concentration-dependent increase in percent apoptosis, there 
is only about a 10% increase in apoptosis following a fivefold increase in the 
concentration of phylloquinone. This could be caused by a number of factors 
including receptor saturation, desensitization, or activation of a different apoptotic 
pathway. The results of these experiments validate the role of phylloquinone in the 
induction of apoptosis.  
 
 
Apoptotic and Non-Apoptotic U937 Cell Areas are Larger Following Treatment with 
Increasing Concentrations of Phylloquinone 
Cell area data and analyses demonstrate treatment with phylloquinone 
results in U937 cells with considerably larger areas, regardless if the cell is 
apoptotic or not (Figures 7 – 16). In addition, this effect is concentration-dependent, 
so that increasing concentrations of phylloquinone result in increasing cell areas. 
 78 
This data supports the preliminary data and is believed to be due, in part, to the 
increased occurrence of apoptosis in treated cell populations (Blair and Miller 
2012). The effect of increased area in non-apoptotic U937 cells treated with 
phylloquinone could also be due to phylloquinone’s ability to regulate cell size 
independently of cell death or because these cells were bound for death but did not 
emit the signals indicative of early or late-stage apoptosis (i.e. annexin V or APO-
BrdU). The results of these experiments show that phylloquinone treatment 
increases cell size, regardless of the status of cell death. 
 
Early-Stage Apoptotic Cells are Smaller than Late-Stage Apoptotic Cells 
Cell area data and analyses demonstrate early-stage apoptotic cells (annexin 
V binding) have areas that are smaller than non-apoptotic cells (annexin V non-
binding), while late-stage apoptotic cells (APO-BrdU binding) have areas that are 
larger than non-apoptotic cells (APO-BrdU non-binding) (Figures 9 – 19). This data 
supports preliminary data in that it provides evidence that apoptotic cells are 
ultimately larger than non-apoptotic ones (Blair and Miller 2012). This change in 
cell area was originally believed to be due to membrane blebbing, however, this 
event occurs earlier in apoptosis, and these changes in area do not seem to appear 
until late-stage apoptosis. This increase in cell area is therefore believed to be due to 
the formation of apoptotic bodies that occurs during the latter part of apoptosis, 
and/or to other cellular mechanisms that could have been employed to increase the 
area of apoptotic cells, such as macrophage differentiation. It is important to note 
that although cells not binding annexin V or APO-BrdU have areas that increase with 
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increasing concentrations of phylloquinone, there is a significant difference between 
the mean area and distributions of these non-apoptotic cells. There are a number of 
explanations for this difference, including changes that may have occurred to U937 
cells during fixation (APO-BrdU™ TUNEL Assay), cells that were undergoing 
apoptosis did not produce the signals necessary to be classified as apoptotic and 
were therefore considered non-apoptotic, or again, to other cellular mechanisms 
that may have been inducted following treatment with phylloquinone (Zhao et al. 
2014). Regardless of the reason, the relationship between early and late-stage 
apoptosis is unaffected, meaning that early-stage apoptotic cells are smaller than 
late-stage ones. 
 
Phylloquinone Inhibits U937 Cell Growth and These Effects are Enhanced Over Time 
 Cell density data and analyses indicate treatment with phylloquinone 
reduces U937 cell growth, and that phylloquinone exerts its effects in a manner that 
is both concentration- and time-dependent (Figures 20, 21, and 23 – 25). In other 
words, treatment with higher concentrations of phylloquinone further reduces 
U937 cell growth, while longer treatment times further enhance this effect.  These 
results are consistent with preliminary data and validate the inhibitory effects of 
phylloquinone on U937 cell growth (Blair and Miller 2012). One replicate of these 
experiments produced data that is inconsistent with reduced U937 cell viability 
following treatment with phylloquinone (Figure 23). This difference in mean cell 
density is believed to be due to plating heterogeneity or contamination, as data from 
this replicate is considerably different from other density experiments. The results 
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of these experiments confirm the inhibitory effect of phylloquinone on U937 cell 
growth.  
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CHAPTER 5 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
 
 
This study was conducted in order to validate the apoptotic and inhibitory 
effects of phylloquinone in the U937 cell line. These effects were assessed through 
the quantification of cell density and area following treatment with phylloquinone, 
as well as through assay confirmation of the occurrence of apoptosis. The results of 
this study show that treatment with phylloquinone induces apoptosis, reduces cell 
growth, and increases cell area, as well as higher concentrations of phylloquinone 
enhance these effects. These results are significant because they document the 
chemotherapeutic and cytotoxic potential of this analog of vitamin K in a carcinoma 
cell line, and in doing so, support former studies involving this compound, as well as 
the need for additional ones (Wei et al. 2010; Wei et al. 2010; Carr et al. 2011; 
Linsalata et al. 2015; Orlando et al. 2015). The utilization of phylloquinone to induce 
cell death and reduce cancer cell proliferation could lead to the development of 
more effective anti-cancer drugs, as well as the discovery of other preexisting drugs 
whose effects are enhanced in combination with this compound. These results are 
also significant because they provide support for studies concerning the anti-cancer 
effects of nutritive and organic compounds, like vitamins, which are appealing 
because of their lack of damage to healthy tissues, variety of other health benefits, 
like immune system enhancement, and implication for cancer prevention (Mora et 
al. 2008). These results also support other findings regarding the changes in cell size 
that occur during apoptosis, which consist of an initial reduction in cell area 
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followed by an increase in area, which is assumed to occur as a result of membrane 
blebbing or budding (Kerr et al. 1972; Majno and Joris 1995).  
Future studies interested in the anti-cancer effects of this compound, alone 
or in combination with other chemotherapeutic agents, can utilize this study when 
selecting experimental model (i.e. cell type), phylloquinone concentration, and 
treatment time.  Future studies on this compound may also provide further insight 
into the evasion of cell death and promotion of tumorgenesis and metastasis, and 
how to intercede this behavior and dysfunction in cancer cells. These research areas 
are of particular importance to our understanding of cancer development, improved 
treatments, and improved prevention.  
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